Comirnaty provisionally approved for individuals 5 years and over in Australia

6 December 2021

Australia’s Therapeutic Goods Administration (TGA) has provisionally approved the COVID-19 vaccine Comirnaty for use in individuals five years and older, which will be marketed by the local subsidiary of US pharma giant Pfizer (NYSE: PFE).

This decision follows the provisional approvals granted by the TGA to Pfizer Australia for the use of Comirnaty in individuals 12 years and older on July 22, 2021 and the booster dose for use in adults 18 years and older on October 26, 2021.

Developed by Germany’s BioNTech (Nasdaq: BNTX) in partnership with Pfizer, Comirnaty has become the most prescribed vaccine against the coronavirus in the western world, generating direct sales of $13 billion in the third quarter of this year and with annual sales expected to top $36 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK